-
Tiziana Life Sciences (TLSA) not to engage in capital raising activities for the immediate future
-
Tiziana Life Sciences (TLSA) Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
-
Tiziana Life Sciences (TLSA) Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
-
Tiziana Life Sciences (TLSA) Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
-
Tiziana Life Sciences (TLSA) Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
-
Tiziana Life Sciences (TLSA) Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
-
Tiziana Life Sciences (TLSA) Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
-
Tiziana Life Sciences (TLSA) Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
-
Tiziana Life Sciences (TLSA) Appoints Ivor Elrifi as CEO
-
Tiziana Life Sciences (TLSA) Regains Nasdaq Compliance
-
Tiziana Life Sciences (TLSA) Granted FDA Fast Track Designation
-
Tiziana Life Sciences (TLSA) Receives $3.4 Million in Non-Dilutive Funding
-
Tiziana Life Sciences (TLSA) Announces FDA Acceptance of Fast Track Designation Submission for Treatment of Multiple Sclerosis

